SYROS PHARMACEUTICALS INC (SYRS) Stock Price & Overview
NASDAQ:SYRS • US87184Q2066
Current stock price
The current stock price of SYRS is 0.1172 USD. Today SYRS is down by -8.44%. In the past month the price decreased by -34.71%. In the past year, price decreased by -98.13%.
SYRS Key Statistics
- Market Cap
- 3.144M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.03
- Dividend Yield
- N/A
SYRS Stock Performance
SYRS Stock Chart
SYRS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to SYRS. When comparing the yearly performance of all stocks, SYRS is a bad performer in the overall market: 97.59% of all stocks are doing better.
SYRS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SYRS. SYRS has a bad profitability rating. Also its financial health evaluation is rather negative.
SYRS Earnings
SYRS Forecast & Estimates
9 analysts have analysed SYRS and the average price target is 10.71 USD. This implies a price increase of 9038.23% is expected in the next year compared to the current price of 0.1172.
For the next year, analysts expect an EPS growth of 73.44% and a revenue growth -100% for SYRS
SYRS Groups
Sector & Classification
SYRS Financial Highlights
Over the last trailing twelve months SYRS reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 19.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -115.08% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SYRS Ownership
SYRS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 398.492B | ||
| AMGN | AMGEN INC | 16.04 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.29 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SYRS
Company Profile
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2016-06-30. The firm is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The firm is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The firm is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
Company Info
IPO: 2016-06-30
SYROS PHARMACEUTICALS INC
35 Cambridge Park Drive
Cambridge MASSACHUSETTS 02140 US
CEO: Nancy Simonian
Employees: 68
Phone: 16177441340
SYROS PHARMACEUTICALS INC / SYRS FAQ
What does SYROS PHARMACEUTICALS INC do?
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2016-06-30. The firm is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The firm is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The firm is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
What is the stock price of SYROS PHARMACEUTICALS INC today?
The current stock price of SYRS is 0.1172 USD. The price decreased by -8.44% in the last trading session.
Does SYRS stock pay dividends?
SYRS does not pay a dividend.
How is the ChartMill rating for SYROS PHARMACEUTICALS INC?
SYRS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in SYROS PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SYRS.
What is the expected growth for SYRS stock?
The Revenue of SYROS PHARMACEUTICALS INC (SYRS) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of SYRS stock?
SYROS PHARMACEUTICALS INC (SYRS) has a market capitalization of 3.14M USD. This makes SYRS a Nano Cap stock.